Xenon Pharmaceuticals Inc. — Form 4
Filed August 13, 2026 · analyzed by the Insider Agent
4
▼ Likely negative
significance 49/100
What the filing says
Director GANNON STEVEN (XENE) sold 10K shares (~$641K) on the open market (84% of holdings). Large sale — ~84% of holdings.
Why this rating
Large sale — ~84% of holdings.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.